Asset Details
Do you wish to reserve the book?
Something Old Brings New Insights: Activity of Cerivastatin Against Thermally Dimorphic Fungi and Its Potential as an Antifungal Scaffold
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Something Old Brings New Insights: Activity of Cerivastatin Against Thermally Dimorphic Fungi and Its Potential as an Antifungal Scaffold
Do you wish to request the book?
Something Old Brings New Insights: Activity of Cerivastatin Against Thermally Dimorphic Fungi and Its Potential as an Antifungal Scaffold
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Something Old Brings New Insights: Activity of Cerivastatin Against Thermally Dimorphic Fungi and Its Potential as an Antifungal Scaffold
2026
Overview
Background/Objectives: Species of the Sporothrix genus were used as a biological model to identify potential antifungal compounds within the NIH Clinical Collection library. Methods: A total of 707 compounds were screened for antifungal activity using in vitro susceptibility assays. Compounds exhibiting significant inhibitory effects (growth inhibitions greater than 80%) were further evaluated by determining their minimum inhibitory concentrations (MICs). As cerivastatin demonstrated the highest activity after itraconazole, it was selected for further evaluation, either alone or in combination with itraconazole, using susceptibility assays, electron microscopy, and flow cytometry analyses. Results: Among the screened compounds, twenty-six showed significant inhibition of yeast growth (≥80%). Compounds with previously reported antifungal activity or not used as oral treatment were excluded from further analysis. MIC determination of eleven selected compounds revealed that cerivastatin inhibited the growth of Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa at concentrations of 1.25 µM and 0.6 µM. Combination treatment with cerivastatin and itraconazole resulted in greater inhibition of Sporothrix growth than either agent alone. Flow cytometry and microscopic analyses revealed more pronounced morphophysiological alterations in yeast cells following combination treatment. Conclusions: These findings highlight the potential of cerivastatin as an antifungal agent when used in combination with itraconazole. Furthermore, the chemical scaffold of cerivastatin warrants further investigation as a basis for the development of novel statins with antifungal activity.
